Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn:
”Major Bleeding With Apixaban vs Aspirin
A Subanalysis of the ARTESiA Randomized Clinical Trial
Question In patients with subclinical atrial fibrillation (SCAF) treated with apixaban or aspirin, what are the sites, severity, and factors associated with major bleeding?
Findings In this subanalysis of the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial including 3961 patients, although the rate of major gastrointestinal bleeding was higher with apixaban compared with aspirin, critical site, intracranial bleeding, and fatal bleeding were similar between arms.
Most major bleeding events in both groups were characterized by decreased hemoglobin and were not emergencies.
Meaning This study found that in patients with SCAF, apixaban increased major gastrointestinal bleeding compared with aspirin but intracranial and fatal bleeding events were similar between groups; most bleeding events were nonemergencies characterized by a decrease in hemoglobin.
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial | Bleeding and Transfusion | JAMA Cardiology | JAMA Network”
Read the full article here.
Article: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
Authors: Deborah M. Siegal, Christian Sticherling, Jeff S. Healey, William F. McIntyre, Lene S. Christensen, Ratika Parkash, Thomas Vanassche, David Conen, Michael Gold, Christopher B. Granger, Jens Cosedis Nielsen, Marc Carrier, Daniel M. Wojdyla, Julia W. Erath, Lena Rivard, Valentina Kutyifa, David J. Wright, Renato D. Lopes
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 03:26Project Elevate Her – Scaling Heights for Bleeding Disorders Awareness – WFH
-
Sep 5, 2026, 03:20Sarah Bassiony: How Do non-Specialists Learn Haematology? – Participate in Our Remote Study
-
Sep 5, 2026, 03:13Omid Seidizadeh: Uncovering the Genetic Architecture of Low Von Willebrand Factor
-
Sep 5, 2026, 03:07Luke McLaughlin: The First Community Article of the Haemophilia Rights Project
-
Sep 5, 2026, 03:00Panagiotis Christoforou: Proud to Contribute to Barts Health’s Leading Role in UK Clinical Trials
-
Sep 5, 2026, 02:51Kassiani Maria Nastouli: Honored to Be Cited in the New ESC Guidelines on the Management of CVD and CKD
-
Sep 5, 2026, 02:44Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
-
Sep 5, 2026, 02:35Balaji Balagani: Exploring Stable vs Unstable vs Complete Coronary Block
-
Sep 5, 2026, 02:28N. Mariana S. Vasquez: Warm vs Cold Autoimmune Hemolytic Anemia for USMLE/NBME Questions